Global Market for Jak and Pi3k Therapy/Inhibitors to Reach $2.2 Billion in 2018; Tofacitinib Moving At 70.9% CAGR

According to a new report from BCC Research, the global market for signal transduction therapies/inhibitors (JAK and PI3K) is expected to grow to $2.2 billion by 2018, with a five-year compound annual growth rate (CAGR) of 36.8%. Tofacitinib, the fastest growing segment, is expected to register a phenomenal CAGR of 70.9%.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
SAMPLE FIGURE GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), 2011-2018 ($ MILLIONS)

SAMPLE FIGURE GLOBAL REVENUE OF SIGNAL TRANSDUCTION THERAPIES/INHIBITORS (JAK AND PI3K), 2011-2018 ($ MILLIONS)

Global Market for Jak and Pi3k Therapy/Inhibitors to Reach $2.2 Billion in 2018

(PRWEB) May 08, 2014

BCC Research (http://www.bccresearch.com) reveals in its new report, JAK AND PI3K SIGNALING PATHWAY MARKETS ,the global market for signal transduction therapies/inhibitors (JAK and PI3K) is expected to grow to $2.2 billion by 2018, with a five-year compound annual growth rate (CAGR) of 36.8%. Tofacitinib, the fastest growing segment, is expected to register a phenomenal CAGR of 70.9%

The commercialization of two JAK therapies/inhibitors—ruxolitinib (Jakafi) from Incyte Corp. for myelofibrosis and tofacitinib (Xeljanz) from Pfizer for rheumatoid arthritis—has provided a much-needed direction to develop target therapies for fatal diseases like cancer and inflammatory diseases.

Tofacitinib, far and away the dominant product in this market, was valued at $90.7 million in 2013 and is projected to reach $1.3 billion by 2018.

Meanwhile, ruxolitinib, which is moving at a significant 19.3% CAGR, is expected to reach $904.8 million in 2018.

“The growing market of therapies related to JAK and PI3K signal pathways have tremendous opportunity to grow since these therapies have the potential to target diseases like cancer and inflammatory diseases with no appropriate medications so far,” says BCC Research pharmaceutical analyst Shalini Shahani Dewan. “The current therapies are capable of reducing the disease burden but cannot cure. Furthermore, there is a growing patient base worldwide for cancers and inflammatory diseases.”

JAK AND PI3K SIGNALING PATHWAY MARKETS provides an overview of the global market for signal transduction therapies and inhibitors, including analyses of global market trends, with data from 2012 and 2013, and projections of CAGRs through 2018. It also presents information on approved products such as Ruxolitnib, as well as others in development. In addition, the study discusses the regulatory environment which is impacting development, relevant patent analyses, and provides profiles of leading companies in the industry.

This report is intended for product developers/manufacturers/producers, multinationals, scientists, researchers, research universities, government and non-government organizations, and others interested in where this market is headed over the next five years.

Editors and reporters who wish to speak with the analyst, should contact Steven Cumming at steven.cumming(at)bccresearch(dot)com.

About BCC Research

BCC Research publishes market research reports that make organizations worldwide more profitable with intelligence that drives smart business decisions. These reports cover today's major industrial and technology sectors, including emerging markets. For more than 40 years we've helped customers identify new market opportunities with accurate and reliable data and insight, including market sizing, forecasting, industry overviews, and identification of significant trends and key competitors. We partner with analysts who are experts in specific areas of industry and technology, providing unbiased measurements and assessments of global markets. Our clients include the top companies in industries around the world as well as universities, business schools, start-ups, consulting firms and investment companies. BCC Research is a unit of Eli Research LLC. Visit our website at http://www.bccresearch.com. Contact us: (+1) 781-489-7301 (U.S. Eastern time), or email information(at)bccresearch(dot)com.

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC, 49-2 Walnut Park, Wellesley, MA 02481, Telephone: (+1) 781-489-7301; Email: editor(at)bccresearch(dot)com as the source and publisher. Thank you.


Contact